LEADER 05452nam 2200601 450 001 9910464527303321 005 20200520144314.0 010 $a92-4-069225-8 035 $a(CKB)3710000000198671 035 $a(EBL)1741837 035 $a(SSID)ssj0001381921 035 $a(PQKBManifestationID)12587706 035 $a(PQKBTitleCode)TC0001381921 035 $a(PQKBWorkID)11438286 035 $a(PQKB)11022400 035 $a(MiAaPQ)EBC1741837 035 $a(Au-PeEL)EBL1741837 035 $a(CaPaEBR)ebr10931308 035 $a(OCoLC)884015862 035 $a(EXLCZ)993710000000198671 100 $a20140925h20142014 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 04$aThe selection and use of essential medicines $ereport of the WHO Expert Committee, 2013 (including the 18th WHO Model List of Essential Medicines and the 4th WHO Model List of Essential Medicines for Children) /$fWorld Health Organization 210 1$aGeneva, Switzerland :$cWorld Health Organization,$d2014. 210 4$dİ2014 215 $a1 online resource (235 p.) 225 1 $aWHO Technical Report Series ;$v985 300 $aDescription based upon print version of record. 311 $a92-4-120985-2 320 $aIncludes bibliographical references. 327 $aCover; Contents; Executive summary; List of participants; Declarations of interests; 1. Introduction; 2. Open session; 3. General items; 3.1 Defining public health relevance; 3.2 Medicines information as a global public good; 3.3 Other; 4. Applications only for paediatric medicines; Section 1: Anaesthetics; Anaesthetics (review) - Children; Section 2: Non-steroidal anti-inflammatory medicines (NSAIMs) and medicines used to treat gout and disease-modifying agents in rheumatoid disorders (DMARDs); 2.2: Opioid analgesics; Section 6: Anti-infective medicines; 6.2: Antibacterials 327 $a6.4: Antiviral medicines6.5: Antiprotozoal medicines; Section 8: Antineoplastics; 8.4: Medicines used in palliative care; Section 11: Blood products and plasma substitutes; 11.1: Plasma substitutes; Section 12: Cardiovascular medicines; 12.2: Antiarrhythmic medicines; 12.6: Lipid-lowering agents; Section 15: Disinfectants and antiseptics; 15.1: Antiseptics; Section 24: Medicines for mental and behavioural disorders; 24.1: Medicines used in psychotic disorders; 24.2: Medicines used in mood disorders; Section 28: Ear, nose and throat medicines; Section 29: Specific medicines for neonatal care 327 $a5. Applications for the 18th Model List and the 4th EMLcSection 2: NSAIMs and DMARDs; 2.1: Non-opioids and non-steroidal anti-inflammatory medicines (NSAIMs); 2.3: Medicines used to treat gout; Section 3: Antiallergics and medicines used in anaphylaxis; Section 4: Antidotes and other substances used in poisonings; Section 6: Anti-infective medicines; 6.2: Antibacterials; 6.3: Antifungal medicines; 6.4: Antiviral medicines; 6.5: Antiprotozoal medicines; Section 8: Antineoplastics, immunosuppressives and medicines used in palliative care; 8.2: Cytotoxic and adjuvant medicines 327 $a8.4: Medicines used in palliative careSection 9: Antiparkinsonism medicines; Section 10: Medicines affecting the blood; 10.1: Antianaemia medicines; Section 11: Blood products and plasma substitutes; 11.2: Plasma fractions for specific use; Section 12: Cardiovascular medicines; 12.4: Medicines used in heart failure; Section 13: Dermatological medicines (topical); 13.4: Medicines affecting skin differentiation and proliferation; Section 17: Gastrointestinal medicines; 17.1: Antiulcer medicines; Section 18: Hormones, other endocrine medicines and contraceptives 327 $a18.5: Insulins and other medicines used for diabetesSection 21: Ophthalmological preparations; Section 22: Oxytocics and antioxytocics; 22.1: Oxytocics; Section 24: Medicines for mental and behavioural disorders; 24.1: Medicines used in psychotic disorders; 24.2: Medicines used in mood disorders; Section 27: Vitamins and minerals; Section 28: Ear, nose and throat medicines; 6. Summary of recommendations; 18th WHO Model List of Essential Medicines; 4th Essential Medicines List for Children; Recommendations for reviews; References; Annex 1 18th WHO Model List of Essential Medicines (April 2013) 327 $aAnnex 2 4th WHO Model List of Essential Medicines for Children (April 2013) 330 $aThis report presents the recommendations of the WHO Expert Committee responsible for updating the WHO Model Lists of Essential Medicines. It contains a summary of the Committee's considerations and justifications for additions and changes to the Model Lists including its recommendations. Annexes to the main report include the revised version of the WHO Model List of Essential Medicines (18th edition) and the WHO Model List of Essential Medicines for Children (4th edition). In addition there is a list of all the items on the Model Lists sorted according to their Anatomical Therapeutic Chemical 410 0$aTechnical report series (World Health Organization) ;$v985. 606 $aDrug utilization$vCongresses 608 $aElectronic books. 615 0$aDrug utilization 676 $a615.58 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910464527303321 996 $aThe selection and use of essential medicines$91946880 997 $aUNINA